A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 45 With Moderate to Severe Skin Involvement Due to Lupus
Latest Information Update: 01 Aug 2024
Price :
$35 *
At a glance
- Drugs Tofacitinib (Primary) ; Corticosteroids
- Indications Cutaneous lupus erythematosus; Systemic lupus erythematosus
- Focus Pharmacokinetics
- 19 Dec 2022 Status changed from recruiting to completed.
- 15 Jul 2022 Planned End Date changed from 1 Jun 2024 to 1 Mar 2024.
- 03 Dec 2021 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.